BioSpace News Archive

Precede Biosciences today announced that data from its platform were presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX.

Cocrystal Pharma, Inc. announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A.

Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B.

Geron Corporation today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF).

SpineX Inc. is today announcing close to full recruitment -- over 80% -- of the patient cohort for its clinical trial of its proprietary SCONE™ device.

BIOLASE, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules.

MEDSIR today announced the results from the PARSIFAL-LONG study, a 5-year extended follow-up of the PARSIFAL study on endocrine-sensitive hormone receptor-positive/HER2-negative advanced breast cancer, demonstrating the effectiveness of two combined option therapies (palbociclib-letrozole and palbociclib-fulvestrant) as first-line treatments for metastatic breast cancer.

BioSig Technologies, Inc., a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, issued its 2023 letter to shareholders to recap recent achievements and offer insights about the year ahead.

Treadwell Therapeutics today announced that it is realigning its pipeline, workforce and management structure to support its highest value program and extend its cash runway to prioritize the execution of key near term value drivers and clinical milestones.

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium (“SABCS”).